

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
19 August 2004 (19.08.2004)

PCT

(10) International Publication Number
WO 2004/069812 A1

(51) International Patent Classification⁷: C07D 239/47, A61K 31/505, A61P 31/18

B-2340 Beerse (BE). LEWI, Paulus, Joannes [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DE JONGE, Marc, René [NL/NL]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). KOYMAN, Lucien, Maria, Henricus [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DAEYAERT, Frederik, Frans, Desire [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VINKERS, Hendrik, Maarten [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number: PCT/EP2004/001011

(22) International Filing Date: 4 February 2004 (04.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PCT/EP03/01291 7 February 2003 (07.02.2003) EP

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(71) Applicants (for US only): ARTS, Theodora, Joanna, Francisca (heiress of the deceased inventor) [/]; Antwerpsesteenweg, 20, B-2350 Vosselaar (BE). JANSSEN, Graziella, Maria, Constantina (heiress of the deceased inventor) [/BE]; Wilgentakjesdreef 6, B-2300 Turnhout (BE). JANSSEN, Herwig, Josephus, Margareta (heir of the deceased inventor) [/BE]; Koekoeksdreef 47, B-2970 Schilde (BE). JANSSEN, Jasmine, Josée, Werner (heiress of the deceased inventor) [/BE]; Zinkvalstraat 5, B-2360 Aartselaar (BE). JANSSEN, Paul, Peter, Maria (heir of the deceased inventor) [/BE]; Grotesteenweg-Zuid 4, B-9052 Zwijnaarde (BE). JANSSEN, Maroussia, Godelieve, Frank (heiress of the deceased inventor) [/BE]; Drève du Carmel 17, B-1410 Waterloo (BE). GUILLEMONT, Jérôme, Emile, Georges [FR/FR]; Janssen-Cilag, 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). PASQUIER, Elisabeth, Therese, Jeanne [FR/FR]; Janssen-Cilag, 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR).

(72) Inventor: JANSSEN, Paul, Adriaan, Jan (deceased).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HEERES, Jan [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30,

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,

[Continued on next page]

(54) Title: PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION



comprising them.

(57) Abstract: This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing $a^1=a^2=a^3=a^4$ and $b^1=b^2=b^3=b^4$ represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyrazinyl; and pharmaceutical compositions

A1

WO 2004/069812



ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION

The present invention concerns pyrimidine derivatives for the prevention of HIV infection. In particular, the present invention concerns the use of pyrimidine derivatives for the manufacture of a medicament for the prevention of HIV (Human Immunodeficiency Virus) infection via sexual intercourse and related intimate contact between partners, more in particular the prevention of HIV infection via vaginal sex.

AIDS (acquired Immune Deficiency Syndrome) is the fourth leading cause of death worldwide and the number one cause of death in Africa. There is still no effective treatment or vaccine against AIDS.

Therefore, in order to be able to control the AIDS/HIV epidemic, it is of the utmost importance to prevent the transmission of the HI Virus.

Sexual transmission is the prevalent mode of transmission of HIV. Said sexual HIV transmission is perfectly preventable by consistent and correct condom use. However, despite intensive prevention programs to increase condom use, condoms are still not systematically used, especially in Third World cultures and these cultures are heavily affected by the AIDS/HIV epidemic. Especially in the developing countries, men do not accept condoms, do not like to use them and women often lack the power to determine when, where and how sexual intercourse takes place and therefore are often not in the position to impose the use of condoms.

Therefore, alternatives to condom use for the protection against sexually transmitted infections, especially HIV, are crucial.

An efficacious alternative to condoms are microbicides for topical use. A microbicide is a chemical entity that can prevent or reduce transmission of sexually transmitted infections when applied to the site where the transmission takes place.

Several categories of microbicides have already been evaluated for their use in preventing HIV transmission : products which have a detergent-surfactant like mode of action (e.g. nonoxynol-9), but said products may cause damage to the vaginal epithelium; acid buffers; Lactobacilli; negatively charged natural or synthetic products

-2-

which interfere with HIV binding to target cells (e.g. sulfated polysaccharides); HIV multiplication inhibiting agents.

The present invention relates to the use of pyrimidine derivatives to prevent HIV

5 infection, to prevent the transmission of HIV infection via sexual intercourse and related intimate contact between partners.

The pyrimidine compounds exhibit HIV replication inhibiting activity in HIV infected warm-blooded animals. They are particularly characterized by an improved ability to inhibit the replication of mutant strains, i.e. strains which have become resistant to art-
10 known drug(s) (drug or multidrug resistant HIV strains).

Besides their HIV replication inhibiting activity in HIV infected warm-blooded animals, the compounds are also able to prevent the transmission of HIV infection in warm-blooded animals, particularly in humans, via sexual intercourse and related intimate contact between partners. The compounds have the ability to work

15 prophylactic, thus preventing that the warm-blooded animals get infected; they are also able to provide for post-exposure protection, meaning that when the present compounds are applied after the sexual intercourse and related intimate contact between partners has taken place, they are still able to prevent HIV infection. Furthermore, the compounds have little or no immunosuppressive activity at a therapeutic effective dose.

20

Compounds structurally related to the present compounds are disclosed in the prior art.

WO 99/50250 and WO 00/27825 disclose substituted aminopyrimidines having HIV replication inhibiting properties.

25 WO 97/19065 discloses substituted 2-anilinopyrimidines useful as protein kinase inhibitors.

WO 00/62778 concerns cyclic protein tyrosine kinase inhibitors.


WO 98/41512 describes substituted 2-anilinopyrimidines useful as protein kinase inhibitors.

30 US 5,691,364 describes benzamidine derivatives and their use as anti-coagulants.

WO 00/78731 describes 5-cyano-2-aminopyrimidine derivatives as KDR kinase or FGFR kinase inhibitors useful in the prophylaxis and treatment of diseases associated with angiogenesis.

35 Thus, one aspect of the invention relates to the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse or related intimate contact between partners, wherein the compound has the formula

-3-



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

$-a^1 \equiv a^2 - a^3 = a^4$ - represents a bivalent radical of formula


n is 0, 1, 2, 3 or 4; and in case $-a^1 = a^2 - a^3 = a^4$ is $(a-1)$, then n may also be 5;

m is 1, 2, 3 and in case $-b^1 = b^2 - b^3 = b^4$ is $(b-1)$, then m may also be 4;

R^1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl;

C₁-6alkyl substituted with formyl, C₁-6alkylcarbonyl, C₁-6alkyloxycarbonyl,

20 C₁-6alkylcarbonyloxy; C₁-6alkyloxyC₁-6alkylcarbonyl substituted with
C₁-6alkyloxycarbonyl;
each R² independently is hydroxy, halo, C₁-6alkyl optionally substituted with cyano or
-C(=O)R⁶, C₃-7cycloalkyl, C₂-6alkenyl optionally substituted with one or more
halogen atoms or cyano, C₂-6alkynyl optionally substituted with one or more halogen
atoms or cyano, C₁-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or
di(C₁-6alkyl)amino, polyhalomethyl, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶,
-C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of
formula



30 wherein each A₁ independently is N, CH or CR⁶; and
A₂ is NH, O, S or NR⁶;
X₁ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, C₁₋₄alkanediyl, -CHOH-, -S-, -S(=O)_p-,
-X₂-C₁₋₄alkanediyl- or -C₁₋₄alkanediyl-X₂;

-4-

X₂ is -NR⁵, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)_p-;

R³ is NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³; -C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; C₁₋₆alkyl substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyl substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷ and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by C₁₋₄alkanediyl; C₁₋₆alkyl substituted with hydroxy and a second substituent selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

10 C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkenyl substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkynyl substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷;

15 X₃ is -NR⁵, -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-, -X₂-C₁₋₄alkanediyl-, -C₁₋₄alkanediyl-X_{2a}-, -C₁₋₄alkanediyl-X_{2b}-C₁₋₄alkanediyl, -C(=N-OR⁸)-C₁₋₄alkanediyl-;

20 with X_{2a} being -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-; and with X_{2b} being -NH-NH-, -N=N-, -C(=O)-, -S-, -S(=O)_p-;

R⁴ is halo, hydroxy, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyl, formyl, amino, mono- or di(C₁₋₄alkyl)amino or R⁷;

25 R⁵ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl or C₁₋₆alkylcarbonyloxy; C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;

R⁶ is C₁₋₄alkyl, amino, mono- or di(C₁₋₄alkyl)amino or polyhaloC₁₋₄alkyl;

30 R⁷ is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro,

35

-5-

polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸), R^{7a}, -X₃-R^{7a} or R^{7a}-C₁₋₄alkyl;

R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro,

10 polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸); R⁸ is hydrogen, C₁₋₄alkyl, aryl or arylC₁₋₄alkyl;

R⁹ and R¹⁰ each independently are hydrogen; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

20 R⁹ and R¹⁰ may be taken together to form a bivalent or trivalent radical of formula

- CH₂-CH₂-CH₂-CH₂- (d-1)
- CH₂-CH₂-CH₂-CH₂-CH₂- (d-2)
- CH₂-CH₂-O-CH₂-CH₂- (d-3)
- 25 -CH₂-CH₂-S-CH₂-CH₂- (d-4)
- CH₂-CH₂-NR¹²-CH₂-CH₂- (d-5)
- CH₂-CH=CH-CH₂- (d-6)
- =CH-CH=CH-CH=CH- (d-7)

R¹¹ is cyano; C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino or aminocarbonyl; C₁₋₄alkylcarbonyl; C₁₋₄alkyloxycarbonyl; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl;

30 R¹² is hydrogen or C₁₋₄alkyl;

R¹³ and R¹⁴ each independently are C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl, C₂₋₆alkenyl optionally substituted with cyano or aminocarbonyl,

35 C₂₋₆alkynyl optionally substituted with cyano or aminocarbonyl;

R¹⁵ is C₁₋₆alkyl substituted with cyano or aminocarbonyl;

R¹⁶ is C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl, or R⁷;

-6-

p is 1 or 2;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁-6alkyl, hydroxyC₁-6alkyl, aminoC₁-6alkyl, mono or di(C₁-6alkyl)aminoC₁-6alkyl, C₁-6alkylcarbonyl,

5 C₃-7cycloalkyl, C₁-6alkyloxy, C₁-6alkyloxycarbonyl, C₁-6alkylthio, cyano, nitro, polyhaloC₁-6alkyl, polyhaloC₁-6alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷.

As used hereinbefore or hereinafter C₁-4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon

10 atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl; C₁-6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the group defined for C₁-4alkyl and pentyl, hexyl, 2-methylbutyl and the like; C₂-6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 2 to 6 carbon atoms such as

15 ethyl, propyl, 1-methylethyl, butyl, pentyl, hexyl, 2-methylbutyl and the like; C₁-4alkanediyl defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 4 carbon atoms such as methylene, 1,2-ethanediyl or 1,2-ethylidene, 1,3-propanediyl or 1,3-propylidene, 1,4-butanediyl or 1,4-butylidene and the like; C₃-7cycloalkyl is generic to cyclopropyl, cyclobutyl,

20 cyclopentyl, cyclohexyl and cycloheptyl; C₂-6alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like; C₂-6alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the

25 like; a monocyclic, bicyclic or tricyclic saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and comprising at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic carbocycle represents an aromatic ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of 4n + 2 electrons, that is with 6, 10, 14 etc. π-electrons (rule of

30 Hückel); a monocyclic, bicyclic or tricyclic saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, said ring system containing only single bonds; a monocyclic, bicyclic,

35

-7-

or tricyclic partially saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, and at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic heterocycle represents an aromatic ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S.

Particular examples of monocyclic, bicyclic or tricyclic saturated carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4,2,0]octanyl, cyclononanyl, cyclodecanyl, decahydronaphthalenyl, 10 tetradecahydroanthracenyl and the like.

Particular examples of monocyclic, bicyclic or tricyclic partially saturated carbocycles are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[4,2,0]octenyl, cyclononenyl, cyclodecenyl, octahydronaphthalenyl, 15 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4,4a,9,9a,10-octahydro-anthracenyl and the like.

Particular examples of monocyclic, bicyclic or tricyclic aromatic carbocycles are phenyl, naphthalenyl, anthracenyl.

20 Particular examples of monocyclic, bicyclic or tricyclic saturated heterocycles are tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 25 trithianyl, decahydroquinolinyl, octahydroindolyl and the like.

Particular examples of monocyclic, bicyclic or tricyclic partially saturated heterocycles are pyrrolinyl, imidazolinyl, pyrazolinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 30 2,3-dihydro-1,4-benzodioxinyl, indolinyl and the like.

Particular examples of monocyclic, bicyclic or tricyclic aromatic heterocycles are azetyl, oxetylidenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, 35 indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl,

-8-

- quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, naphthiridinyl, pteridinyl, benzopyranyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl,
- 5 thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl,
- 10 oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, isoxazolotriazinyl, isothiazolotriazinyl,
- 15 pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like.

- As used herein before, the term (=O) forms a carbonyl moiety when attached to a
- 20 carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.

- Whenever used hereinbefore or hereinafter that substituents can be selected each independently out of a list of numerous definitions, such as for example for R⁹ and R¹⁰,
- 25 all possible combinations are intended which are chemically possible and which lead to chemically stable molecules.

- The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalomethyl as a group or part of a group is defined as mono- or
- 30 polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl; polyhaloC₁₋₄alkyl or polyhaloC₁₋₆alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C₁₋₄alkyl or C₁₋₆alkyl, for example, the groups defined in halomethyl, 1,1-difluoro-ethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhalomethyl, polyhaloC₁₋₄alkyl or polyhaloC₁₋₆alkyl, they may be the same or different.
- 35

-9-

The term heterocycle in the definition of R⁷ or R^{7a} is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises 1*H*-pyrrolyl and 2*H*-pyrrolyl.

5 The carbocycle or heterocycle in the definition of R⁷ or R^{7a} may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like, or when the carbocycle is naphthalenyl, it may be 1-naphthalenyl, 2-naphthalenyl and the like.

10 When any variable (eg. R⁷, X₂) occurs more than one time in any constituent, each definition is independent.

15 Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.

For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or 20 purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

25 The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy- 30 acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

35 The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with

-10-

appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine,

5 ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine

10 salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely the salt form can be converted by treatment with acid into the free acid form.

The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, 15 alcoholates and the like.

The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as,

20 for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen.

Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate 25 and acetate. The counterion of choice can be introduced using ion exchange resins.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called *N*-oxide.

30 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth

35 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxyic acid or halo substituted benzenecarboperoxyic acid, e.g. 3-chlorobenzene-carbo-

-11-

peroxyoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

5

It will be appreciated that some of the compounds of formula (I) and their *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

10 The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I), and their *N*-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures

15 containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their *N*-oxides, salts, solvates or quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Thus, when a compound of formula (I) is for instance specified as (E), this

20 means that the compound is substantially free of the (Z) isomer.

In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the *cis*- or *trans*- configuration. Compounds encompassing double bonds can have an E (entgegen) or Z (zusammen)-stereochemistry at said double bond. The terms *cis*, *trans*, R, S, E and Z

25 are well known to a person skilled in the art.

Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.

For some of the compounds of formula (I), their *N*-oxides, salts, solvates or quaternary amines and the intermediates used in the preparation thereof, the absolute

30 stereochemical configuration was not experimentally determined. In these cases the stereoisomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" stereoisomeric forms can be unambiguously characterized by for instance their optical rotation in case "A" and "B" have an enantiomeric relationship. A

35 person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction. In case "A" and "B" are stereoisomeric mixtures, they can be further separated whereby the

-12-

respective first fractions isolated are designated "A1" and "B1" and the second as "A2" and "B2", without further reference to the actual stereochemical configuration.

Pure stereochemically isomeric forms of the present compounds and the intermediates which intervene in the chemical synthesis thereof, can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective or fractional crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers, for instance by treatment with alkali. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.


Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

Whenever used hereinafter, the term "compounds of formula (I)" is meant to also include their *N*-oxide forms, their salts, their quaternary amines and their stereochemically isomeric forms. Of special interest are those compounds of formula (I) which are stereochemically pure.

An interesting group of compounds are those compounds of formula (I) wherein $-a^1=a^2-a^3=a^4-$ represents a bivalent radical of formula $-CH=CH-CH=CH-$ (a-1).


-13-

Also an interesting group of compounds are those compounds of formula (I) having the formula




the *N*-oxides, the pharmaceutically acceptable addition salts, the quaternary amines or
 5 the stereochemically isomeric forms thereof, wherein
 $-a^1=a^2-a^3=a^4$, $b^1=b^2-b^3=b^4$, R^1, R^2, R^3, R^4, m and X_1 are as defined hereinabove;
 n' is 0, 1, 2 or 3 and in case $-a^1=a^2-a^3=a^4$ is (a-1), then n' may also be 4;
 R^2 is halo, C_{1-6} alkyl, trihalomethyl, cyano, aminocarbonyl, C_{1-6} alkyl substituted with
 cyano or aminocarbonyl;
 10 provided that R^2 is placed at the para position in respect of the NR^1 moiety.

Another interesting group of compounds are those compounds of formula (I) having the formula



15 the *N*-oxides, the pharmaceutically acceptable addition salts, the quaternary amines or
 the stereochemically isomeric forms thereof, wherein
 $-b^1=b^2-b^3=b^4$, R^1, R^2, R^3, R^4, m and X_1 are as defined hereinabove;
 n' is 0, 1, 2, 3 or 4;
 R^2 is halo, C_{1-6} alkyl, trihalomethyl, cyano, aminocarbonyl, C_{1-6} alkyl substituted with
 20 cyano or aminocarbonyl.

Yet a further interesting group of compounds are those compounds of formula (I)
 having the formula




25 the *N*-oxides, the pharmaceutically acceptable addition salts, the quaternary amines or
 the stereochemically isomeric forms thereof, wherein
 R^1, R^2, R^3, R^4 and X_1 are as defined hereinabove;
 n' is 0, 1, 2, 3 or 4;

-14-

R^2 is halo, C_{1-6} alkyl, trihalomethyl, cyano, aminocarbonyl, C_{1-6} alkyl substituted with cyano or aminocarbonyl.

Also particular compounds are those compounds of formula (I), (I'), (I'') or (I''')

- 5 wherein one or wherever possible more of the following conditions apply :
 - a) m is 1, 2 or 3, in particular 2 or 3, more in particular 2, even more in particular m is 2 and said two R^4 substituents are placed in position 2 and 6 (ortho position) in respect of the X_1 moiety;
 - b) m is 1, 2 or 3 and R^3 is placed in position 4 (para position) in respect of the X_1 moiety;
 - c) X_1 is $-NR^5$, $-NH-NH$, $-N=N$, $-O-$, $-C(=O)-$, C_{1-4} alkanediyl, $-CHOH-$, $-S(=O)_p-$, $-X_2-C_{1-4}$ alkanediyl- or $-C_{1-4}$ alkanediyl- X_2- ;
 - d) where applicable n' is 0;
 - e) where applicable n is 1 and said R^2 substituent is placed in position 4 (para position) in respect of the NR^1 -linker;
 - f) R^2 is hydroxy, halo, C_{1-6} alkyl optionally substituted with cyano or $-C(=O)R^6$, C_{3-7} cycloalkyl, C_{2-6} alkenyl optionally substituted with one or more halogen atoms or cyano, C_{2-6} alkynyl optionally substituted with one or more halogen atoms or cyano, C_{1-6} alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_{1-6} alkyl)amino, polyhalomethyl, polyhalomethylthio, $-S(=O)_pR^6$, $-NH-S(=O)_pR^6$, $-NHC(=O)H$, $-C(=O)NHNH_2$, $-NHC(=O)R^6$, $-C(=NH)R^6$ or a radical of formula



wherein each A_1 independently is N, CH or CR^6 ; and

A_2 is NH, O, S or NR^6 ;

- 25 g) R^2 is halo, C_{1-6} alkyl, trihalomethyl, cyano, C_{1-6} alkyl substituted with cyano or aminocarbonyl;
- h) R^2 is cyano, aminocarbonyl or C_{1-6} alkyl substituted with cyano or aminocarbonyl, in particular cyano;
- i) R^2 is cyano, aminocarbonyl or C_{1-6} alkyl substituted with cyano or aminocarbonyl, in particular cyano.

A preferred embodiment of the present compounds encompasses those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is NHR^{13} ; $NR^{13}R^{14}$; $-C(=O)-NHR^{13}$; $-C(=O)-NR^{13}R^{14}$; $-C(=O)-R^{15}$; $-CH=N-NH-C(=O)-R^{16}$; C_{2-6} alkyl substituted with cyano or aminocarbonyl; C_{1-6} alkyl substituted with NR^9R^{10} ; $-C(=O)-NR^9R^{10}$; $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{1-6} alkyl substituted with two or more substituents each.

-15-

independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyl}$ substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by $\text{C}_{1-4}\text{alkanediyl}$; $\text{C}_{1-6}\text{alkyl}$ substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$ optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkynyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$; with R^{9a} representing hydroxy; $\text{C}_{1-6}\text{alkyl}$; $\text{C}_{1-6}\text{alkyloxy}$; $\text{C}_{1-6}\text{alkylcarbonyl}$; $\text{C}_{1-6}\text{alkyloxycarbonyl}$; amino; mono- or di($\text{C}_{1-6}\text{alkyl}$)amino; mono- or di($\text{C}_{1-6}\text{alkyl}$)aminocarbonyl, $-\text{CH}(\text{=NR}^{11})$ or R^7 , wherein each of the aforementioned $\text{C}_{1-6}\text{alkyl}$ groups in the definition of R^{9a} may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, $\text{C}_{1-6}\text{alkyloxy}$, hydroxy $\text{C}_{1-6}\text{alkyloxy}$, carboxyl, $\text{C}_{1-6}\text{alkyloxycarbonyl}$, cyano, amino, imino, mono- or di($\text{C}_{1-4}\text{alkyl}$)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, $-\text{S}(=\text{O})_p\text{R}^6$, $-\text{NH}-\text{S}(=\text{O})_p\text{R}^6$, $-\text{C}(=\text{O})\text{R}^6$, $-\text{NHC}(=\text{O})\text{H}$, $-\text{C}(=\text{O})\text{NHNH}_2$, $-\text{NHC}(=\text{O})\text{R}^6$, $-\text{C}(=\text{NH})\text{R}^6$, R^7 ; R^{9a} may also be taken together with R^{10} to form a bivalent or trivalent radical of formula (d-1), (d-2), (d-3), (d-4), (d-5), (d-6) or (d-7) as defined hereinabove.

A further interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is NHR^{13} ; $\text{NR}^{13}\text{R}^{14}$; $-\text{C}(=\text{O})-\text{NHR}^{13}$; $-\text{C}(=\text{O})-\text{NR}^{13}\text{R}^{14}$; $-\text{C}(=\text{O})-\text{R}^{15}$; $-\text{CH}=\text{N}-\text{NH}-\text{C}(=\text{O})-\text{R}^{16}$; $\text{C}_{1-6}\text{alkyl}$ substituted with NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^{9a}\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyl}$ substituted with two or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyl}$ substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by $\text{C}_{1-4}\text{alkanediyl}$; $\text{C}_{1-6}\text{alkyl}$ substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$ optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkynyl}$ substituted with one or more substituents each independently selected

-16-

from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ;
 $-\text{C}(=\text{N-O-R}^8)\text{-C}_1\text{-alkyl}$; R^7 or $-\text{X}_3\text{-R}^7$; with R^{9a} representing hydroxy; $\text{C}_1\text{-alkyl}$;
 $\text{C}_1\text{-alkyloxy}$; $\text{C}_1\text{-alkylcarbonyl}$; $\text{C}_1\text{-alkyloxycarbonyl}$; amino; mono- or
di($\text{C}_1\text{-alkyl}$)amino; mono- or di($\text{C}_1\text{-alkyl}$)aminocarbonyl, $-\text{CH}(\text{=NR}^{11})$ or R^7 , wherein

5 each of the aforementioned $\text{C}_1\text{-alkyl}$ groups in the definition of R^{9a} may optionally and
each individually be substituted with one or two substituents each independently
selected from hydroxy, $\text{C}_1\text{-alkyloxy}$, hydroxy $\text{C}_1\text{-alkyloxy}$, carboxyl,
 $\text{C}_1\text{-alkyloxycarbonyl}$, cyano, amino, imino, mono- or di($\text{C}_1\text{-alkyl}$)amino,
polyhalomethyl, polyhalomethoxy, polyhalomethylthio, $-\text{S}(=\text{O})_p\text{R}^6$, $-\text{NH-S}(=\text{O})_p\text{R}^6$,

10 $-\text{C}(=\text{O})\text{R}^6$, $-\text{NHC}(=\text{O})\text{H}$, $-\text{C}(=\text{O})\text{NHNH}_2$, $-\text{NHC}(=\text{O})\text{R}^6$, $-\text{C}(=\text{NH})\text{R}^6$, R^7 ; R^{9a} may also
be taken together with R^{10} to form a bivalent or trivalent radical of formula (d-1), (d-2),
(d-3), (d-4), (d-5), (d-6) or (d-7) as defined hereinabove.

Also an interesting group of compounds are those compounds of formula (I), (I'), (I'')
15 or (I''') wherein R^3 is $-\text{CH}=\text{N-NH-C}(=\text{O})\text{-R}^{16}$; $\text{C}_1\text{-alkyl}$ substituted with NR^9R^{10} ,
 $-\text{C}(=\text{O})\text{-NR}^{9a}\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_1\text{-alkyl}$ substituted with two or more
substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_1\text{-alkyl}$ substituted with one or more substituents each
independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 .

20 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by
 $\text{C}_1\text{-alkanediyl}$; $\text{C}_1\text{-alkyl}$ substituted with hydroxy and a second substituent selected from
cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_1\text{-alkyloxyC}_1\text{-alkyl}$
optionally substituted with one or more substituents each independently selected from
cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_2\text{-alkenyl}$ substituted with
25 one or more substituents each independently selected from halo, cyano, NR^9R^{10} ,
 $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_2\text{-alkynyl}$ substituted with one or more
substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $-\text{C}(=\text{N-O-R}^8)\text{-C}_1\text{-alkyl}$; R^7 or $-\text{X}_3\text{-R}^7$; with R^{9a} as defined
hereinabove.

30 Another interesting group of compounds are those compounds of formula (I), (I'), (I'')
or (I''') wherein R^3 is NHR^{13} , $\text{NR}^{13}\text{R}^{14}$, $-\text{C}(=\text{O})\text{-R}^{15}$, $\text{C}_1\text{-alkyl}$ substituted with one or
more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7 ; $\text{C}_1\text{-alkyl}$ substituted with one or more substituents each
35 independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})\text{-NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})\text{-C}_1\text{-alkyl}$ or R^7
and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by
 $\text{C}_1\text{-alkanediyl}$; $\text{C}_1\text{-alkyl}$ substituted with hydroxy and a second substituent selected

-17-

from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$ optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} ,
5 $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkynyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$.

Also interesting are those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is
10 $\text{C}_{1-6}\text{alkyl}$ substituted with NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^{9a}\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ;
 $\text{C}_{1-6}\text{alkyl}$ substituted with two or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyl}$ substituted with one or more substituents each independently selected from cyano, NR^9R^{10} ,
15 $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by $\text{C}_{1-4}\text{alkanediyl}$; $\text{C}_{1-6}\text{alkyl}$ substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$ optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$,
 $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more substituents each
20 independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkynyl}$ substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ;
 $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$; with R^{9a} as defined hereinabove.

Also interesting are those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is
25 $\text{C}_{1-6}\text{alkyl}$ substituted with one or more substituents each independently selected from cyano, NR^9R^{10} or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ substituted with one or more substituents each independently selected from cyano, NR^9R^{10} or R^7 ; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$ substituted with cyano; $\text{C}_{1-6}\text{alkyl}$ substituted with hydroxy and a second substituent selected from cyano or R^7 ; $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$.

Another interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is R^7 .

Still another interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R^3 is $\text{C}_{1-6}\text{alkyl}$ substituted with cyano, in particular $\text{C}_{2-6}\text{alkyl}$

-18-

substituted with cyano, more in particular ethyl or propyl substituted with cyano; or C₂-alkenyl substituted with cyano. Preferred is C₂-alkenyl substituted with cyano.

5 Also an interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R³ is C₁-alkyl substituted with cyano and R⁷, or C₂-alkenyl substituted with cyano and R⁷.

A further interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R³ is C₁-alkyl substituted with R⁷.

10 Still a further interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R³ is -C(=N-O-R⁸)-C₁₋₄alkyl.

15 Also an interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R³ is C₁-alkyl substituted with hydroxy and a second substituent selected from cyano or R⁷.

Also an interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein R² or R^{2'} is cyano or aminocarbonyl and R¹ is hydrogen.

20 Another interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein m is 2 or 3 and X₁ is -NR⁵-, -O-, -C(=O)-, -CH₂-, -CHOH-, -S-, -S(=O)_p-, in particular wherein X₁ is -NR⁵-, or -O-.

25 Also an interesting group of compounds are those compounds of formula (I), (I'), (I'') or (I''') wherein one or more, preferably all of the following restrictions apply :

- a) n is at least 1, in particular 1; or n' is 0;
- b) R² or R^{2'} is cyano;
- c) m is 1, 2 or 3;

30 d) R⁴ is C₁-alkyl, especially methyl; nitro; amino; halo; C₁-alkyloxy or R⁷;

e) R³ is R⁷, NR¹³R¹⁴, -C(=O)R¹⁵, -CH=N-NH-C(=O)R¹⁶, -C(=O)NHR¹³, -C(=O)NR¹³R¹⁴, -C(=N-OR⁸)-C₁₋₄alkyl, C₁-alkyl substituted with cyano, C₁-alkyl substituted twice with cyano, C₁-alkyl substituted with NR⁹R¹⁰, C₁-alkyl substituted with hydroxy and cyano, C₁-alkyl substituted with hydroxy and R⁷, C₁-alkyloxy

35 C₁-alkyl, C₁-alkyloxy C₁-alkyl substituted with cyano, C₂-alkenyl substituted with R⁷, C₂-alkenyl substituted with cyano, C₂-alkenyl substituted twice with cyano, C₂-alkenyl substituted with cyano and R⁷, C₂-alkenyl substituted with cyano and

-19-

$-C(=O)-C_{1-6}\text{alkyl}$, $C_{2-6}\text{alkenyl}$ substituted with cyano and halo, $C_{2-6}\text{alkenyl}$ substituted with $-C(=O)-NR^9R^{10}$, $C_{2-6}\text{alkenyl}$ substituted with halo, $C_{2-6}\text{alkenyl}$ substituted twice with halo or $C_{2-6}\text{alkenyl}$ substituted with NR^9R^{10} ;

f) X_3 is $-C(=O)-$, $-\text{CH}_2-C(=O)-$, or $-C(=N-\text{OR}^8)-C_{1-4}\text{alkanediyl}-$;

5 g) X_1 is NH or O;

h) R^1 is hydrogen or $C_{1-4}\text{alkyl}$.

Preferred compounds of formula (I), (I'), (I'') or (I''') are compounds 1, 25, 84, 133, 152, 179, 233, 239, 247, 248, 255 (see Tables 1, 2 and 3), their *N*-oxides,

10 pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof.

The compounds of formula (I) are disclosed in WO 2003/016306. Their preparation is also described therein. Some of the intermediates and starting materials are known 15 compounds and may be commercially available or may be prepared according to art-known procedures or some of the compounds of formula (I) or the described intermediates may be prepared according to the procedures described in WO 99/50250 and WO 00/27825.

20 The present invention also relates to a novel compound, i.e. 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]benzonitrile (E) (compound 255); a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric from thereof.

Said novel compound can be prepared as follows :

25 a) NaH (60%) (0.0233 mol) was added to a mixture of 4-hydroxy-3,5-dimethyl benzaldehyde (0.0233 mol) in dioxane (35 ml) under N_2 flow. The mixture was stirred for 5 minutes. 1-methyl-2-pyrrolidinone (35 ml) was added. The mixture was stirred for 10 minutes. 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.0212 mol) was added. The mixture was stirred at 155 °C for 12 hours, poured out into H_2O and 30 extracted with CH_2Cl_2 . The organic layer was separated, washed several times with H_2O , dried ($MgSO_4$), filtered and the solvent was evaporated. The residue was purified with column chromatography over silica gel (eluent : CH_2Cl_2 100; 35-70 μm). The pure fractions were collected and the solvent was evaporated. The obtained fraction was crystallized from CH_3CN /diisopropyl ether. The precipitate was filtered off and dried, 35 yielding 2.2 g of intermediate 1.

-20-

b) Potassium tert.-butoxide (0.0065 mol) was added portionwise at 5°C to a mixture of cyanomethyl phosphonic acid diethylester (0.0065 mol) in tetrahydrofuran (20 ml) under N₂ flow. The mixture was stirred at room temperature for 1 hour. A solution of intermediate 1 (0.0044 mol) in tetrahydrofuran (20 ml) was added. The mixture was
5 stirred for 2 hours at room temperature. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.8 g) was crystallized from diethyl ether. The precipitate was filtered off and dried. The residue (1.5 g) was purified by column chromatography over kromasil (eluent: CH₃CN/AcNH₄ 50/50; 10 µm). Two fractions (F1, F2) were collected and the
10 solvent was evaporated. Yield: 0.47 g of F1 and 0.44 g of F2. F1 was crystallized from diisopropyl ether. The precipitate was filtered off and dried, yielding 0.4 g of 4-[[4-[4-(2-cyanoethyl)-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]benzonitrile (E) (compound 255).

15 As already indicated above, the compounds of formula (I), (I'), (I''), (I''') show antiretroviral properties (reverse transcriptase inhibiting properties) in HIV infected warm-blooded animals, in particular against Human Immunodeficiency Virus (HIV), which is the aetiological agent of Acquired Immune Deficiency Syndrome (AIDS) in humans. The HIV virus preferentially infects human T-4 cells and destroys them or
20 changes their normal function, particularly the coordination of the immune system. As a result, an infected patient has an ever decreasing number of T-4 cells, which moreover behave abnormally. Hence, the immunological defense system is unable to combat infections and neoplasms and the HIV infected subject usually dies by opportunistic infections such as pneumonia, or by cancers. Other conditions associated with HIV
25 infection include thrombocytopaenia, Kaposi's sarcoma and infection of the central nervous system characterized by progressive demyelination, resulting in dementia and symptoms such as, progressive dysarthria, ataxia and disorientation. HIV infection further has also been associated with peripheral neuropathy, progressive generalized lymphadenopathy (PGL) and AIDS-related complex (ARC).

30 Due to their antiretroviral properties, particularly their anti-HIV properties, especially their anti-HIV-1-activity, the compounds of formula (I), their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, are useful in the treatment of individuals infected by HIV.

35 The HIV replication inhibiting effect of the compounds of formula (I) is described in WO 2003/016306. Compound 255 has a pIC₅₀ value of 9.00 when tested in the test described under the heading "C. Pharmacological example" of WO 2003/016306.

-21-

It has now been found that the compounds of formula (I) can not only be used to treat HIV infected warm-blooded animals, but that they can also be used to prevent that warm-blooded animals, including humans, get HIV infected via sexual intercourse or

5 related intimate contact between partners. Thus, as already indicated above, the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse or related intimate contact between partners, in particular to prevent HIV-1 infection and further in particular to prevent HIV or HIV-1 infection with (multi) drug resistant HIV strains,

10 i.e. HIV strains, especially HIV-1 strains, that have acquired resistance to one or more art-known non-nucleoside reverse transcriptase inhibitors. Art-known non-nucleoside reverse transcriptase inhibitors are those non-nucleoside reverse transcriptase inhibitors other than the present compounds and in particular commercial non-nucleoside reverse transcriptase inhibitors.

15 The invention also relates to a method of preventing HIV infection via sexual intercourse or related intimate contact between partners comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

The term sexual intercourse or related intimate contact between partners comprises

20 vaginal sex, anal sex, oral sex and contact of body sites with HIV infected fluids of the sexual partner, in particular semen. Particularly, the term sexual intercourse or related intimate contact between partners constitutes vaginal, anal or oral sex, more particularly vaginal sex.

25 The contact sites believed to be most responsible for the transmission of HIV via sexual intercourse or related intimate contact between partners are the genitals, rectum, mouth, hands, lower abdomen, upper thighs.

The term "partners" as mentioned hereinbefore or hereinafter defines two or more

30 warm-blooded animals, in particular humans, who are sexually active with each other, ie. who have sexual intercourse with each other or who have intimate contact with each other related to sexual activities.

The present invention also relates to a pharmaceutical composition comprising a

35 pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound of formula (I) characterized in that the composition is in a form adapted to be applied to the site where the sexual intercourse or related intimate contact

-22-

takes place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth.

As appropriate compositions there may be cited all compositions usually employed for being applied to the vagina, rectum, mouth and skin such as for example gels, jellies,

5 creams, ointments, films, sponges, foams, intravaginal rings, cervical caps, suppositories for rectal or vaginal application, vaginal or rectal or buccal tablets, mouthwashes.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is

10 combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of administration. For example, in preparing the compositions for topical oral administration, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as mouthwashes in the

15 form of a suspension, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of tablets. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for cutaneous administration, the carrier optionally comprises a suitable wetting agent,

20 optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a cream or gel.

25 In order to increase the residence time of the pharmaceutical composition at the site of administration, it may be advantageous to include in the compositions of the present invention a bioadhesive, in particular a bioadhesive polymer. A bioadhesive may be defined as a material that adheres to a live biological surface such as for example a

30 mucus membrane or skin tissue. The term bioadhesive is well-known to the person skilled in the art. Thus, the present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound of formula (I) characterized in that the pharmaceutical composition is bioadhesive to the site of application. Preferably, the site of application is the vagina, rectum, mouth or skin, most preferred is the vagina.

-23-

Examples of bioadhesives which may be used in the pharmaceutical compositions of the present invention comprise polyacrylic acid derivatives, such as for example carbopol or polycarbophil, e.g. carbopol 934P, carbopol 940, polycarbophil AA1; cellulose ether derivatives such as for example hydroxypropyl methylcellulose,

5 hydroxypropyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, chitosan; natural polymers such as for example alginates, tragacanth, inulin; pregelatinized starch.

An embodiment of the present invention relates to a gel containing carbopol,

10 hydroxypropyl cellulose, hydroxyethyl cellulose or pregelatinized starch.

To aid solubility of the compounds of formula (I), suitable ingredients, e.g. cyclodextrins, may be included in the compositions. Appropriate cyclodextrins are α -, β -, γ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the

15 hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C₁₋₆alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated β -CD; hydroxyC₁₋₆alkyl, particularly hydroxyethyl, hydroxy-propyl or hydroxybutyl; carboxyC₁₋₆alkyl, particularly carboxymethyl or carboxy-ethyl; C₁₋₆alkylcarbonyl, particularly acetyl. Especially noteworthy as complexants and/or solubilizers are β -CD, randomly methylated β -CD, 2,6-dimethyl- β -CD, 2-hydroxyethyl- β -CD, 2-hydroxyethyl- β -CD, 2-hydroxypropyl- β -CD and (2-carboxymethoxy)propyl- β -CD, and in particular 2-hydroxypropyl- β -CD (2-HP- β -CD).

The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxy-propyl and hydroxyethyl.

The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The M.S. and D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. Preferably, as measured by mass spectrometry, the M.S. ranges from 0.125 to 10 and the D.S. ranges from 0.125 to 3.

-24-

The compounds of formula (I) may be formulated in the pharmaceutical compositions of the present invention in the form of particles consisting of a solid dispersion comprising a compound of formula (I) and one or more appropriate pharmaceutically acceptable water-soluble polymers.

5

The term "a solid dispersion" used hereinafter defines a system in a solid state (as opposed to a liquid or gaseous state) comprising at least two components, in casu the compound of formula (I) and the water-soluble polymer, wherein one component is dispersed more or less evenly throughout the other component or components (in case 10 additional pharmaceutically acceptable formulating agents, generally known in the art, are included, such as plasticizers, preservatives and the like). When said dispersion of the components is such that the system is chemically and physically uniform or homogenous throughout or consists of one phase as defined in thermo-dynamics, such a solid dispersion will be called "a solid solution". Solid solutions are preferred physical 15 systems because the components therein are usually readily bioavailable to the organisms to which they are administered. This advantage can probably be explained by the ease with which said solid solutions can form liquid solutions when contacted with a liquid medium such as the gastro-intestinal juices. The ease of dissolution may be attributed at least in part to the fact that the energy required for dissolution of the 20 components from a solid solution is less than that required for the dissolution of components from a crystalline or microcrystalline solid phase.

The term "a solid dispersion" also comprises dispersions which are less homogenous throughout than solid solutions. Such dispersions are not chemically and physically 25 uniform throughout or comprise more than one phase. For example, the term "a solid dispersion" also relates to a system having domains or small regions wherein amorphous, microcrystalline or crystalline compound of formula (I), or amorphous, microcrystalline or crystalline water-soluble polymer, or both, are dispersed more or less evenly in another phase comprising water-soluble polymer, or compound of 30 formula (I), or a solid solution comprising compound of formula (I) and water-soluble polymer. Said domains are regions within the solid dispersion distinctively marked by some physical feature, small in size, and evenly and randomly distributed throughout the solid dispersion.

35 Various techniques exist for preparing solid dispersions including melt-extrusion, spray-drying and solution-evaporation.

-25-

The solution-evaporation process comprises the following steps :

- a) dissolving the compound of formula (I) and the water-soluble polymer in an appropriate solvent, optionally at elevated temperatures;
- b) heating the solution resulting under point a), optionally under vacuum, until the 5 solvent is evaporated. The solution may also be poured onto a large surface so as to form a thin film, and evaporating the solvent therefrom.

In the spray-drying technique, the two components are also dissolved in an appropriate solvent and the resulting solution is then sprayed through the nozzle of a spray dryer 10 followed by evaporating the solvent from the resulting droplets at elevated temperatures.

The preferred technique for preparing solid dispersions is the melt-extrusion process comprising the following steps :

- 15 a) mixing a compound of formula (I) and an appropriate water-soluble polymer,
- b) optionally blending additives with the thus obtained mixture,
- c) heating and compounding the thus obtained blend until one obtains a homogenous melt,
- d) forcing the thus obtained melt through one or more nozzles; and
- e) cooling the melt till it solidifies.

The terms "melt" and "melting" should be interpreted broadly. These terms not only mean the alteration from a solid state to a liquid state, but can also refer to a transition to a glassy state or a rubbery state, and in which it is possible for one component of the 25 mixture to get embedded more or less homogeneously into the other. In particular cases, one component will melt and the other component(s) will dissolve in the melt thus forming a solution, which upon cooling may form a solid solution having advantageous dissolution properties.

30 After preparing the solid dispersions as described hereinabove, the obtained products can be optionally milled and sieved.

The solid dispersion product may be milled or ground to particles having a particle size of less than 600 µm, preferably less than 400 µm and most preferably less than 125 µm.

35 The particles prepared as described hereinabove can then be formulated by conventional techniques into the pharmaceutical dosage forms of the present invention.

-26-

It will be appreciated that a person of skill in the art will be able to optimize the parameters of the solid dispersion preparation techniques described above, such as the most appropriate solvent, the working temperature, the kind of apparatus being used,
5 the rate of spray-drying, the throughput rate in the melt-extruder

The water-soluble polymers in the particles are polymers that have an apparent viscosity, when dissolved at 20°C in an aqueous solution at 2 % (w/v), of 1 to 5000 mPa.s more preferably of 1 to 700 mPa.s, and most preferred of 1 to 100 mPa.s. For
10 example, suitable water-soluble polymers include alkylcelluloses, hydroxyalkyl-celluloses, hydroxyalkyl alkylcelluloses, carboxyalkylcelluloses, alkali metal salts of carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters, starches, pectines, chitin derivates, di-, oligo- and polysaccharides such as trehalose, alginic acid or alkali metal and ammonium salts thereof, carrageenans, galactomannans,
15 tragacanth, agar-agar, gummi arabicum, guar gummi and xanthan gummi, polyacrylic acids and the salts thereof, polymethacrylic acids and the salts thereof, methacrylate copolymers, polyvinylalcohol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate, combinations of polyvinylalcohol and polyvinylpyrrolidone, polyalkylene oxides and copolymers of ethylene oxide and
20 propylene oxide. Preferred water-soluble polymers are hydroxypropyl methylcelluloses.

Also one or more cyclodextrins can be used as water soluble polymer in the preparation of the above-mentioned particles as is disclosed in WO 97/18839. Said cyclodextrins
25 include the pharmaceutically acceptable unsubstituted and substituted cyclodextrins known in the art, more particularly α , β or γ cyclodextrins or the pharmaceutically acceptable derivatives thereof.

Substituted cyclodextrins which can be used to prepare the above described particles
30 include polyethers described in U.S. Patent 3,459,731. Further substituted cyclodextrins are ethers wherein the hydrogen of one or more cyclodextrin hydroxy groups is replaced by C₁-6alkyl, hydroxyC₁-6alkyl, carboxy-C₁-6alkyl or C₁-6alkyloxycarbonylC₁-6alkyl or mixed ethers thereof. In particular such substituted cyclodextrins are ethers wherein the hydrogen of one or more cyclodextrin hydroxy groups is replaced by C₁-3alkyl, hydroxyC₂-4alkyl or carboxyC₁-2alkyl or more in
35 particular by methyl, ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxymethyl or carboxyethyl.

Of particular utility are the β -cyclodextrin ethers, e.g. dimethyl- β -cyclodextrin as described in Drugs of the Future, Vol. 9, No. 8, p. 577-578 by M. Nogradi (1984) and polyethers, e.g. hydroxypropyl β -cyclodextrin and hydroxyethyl β -cyclodextrin, being examples. Such an alkyl ether may be a methyl ether with a degree of substitution of about 0.125 to 3, e.g. about 0.3 to 2. Such a hydroxypropyl cyclodextrin may for example be formed from the reaction between β -cyclodextrin and propylene oxide and may have a MS value of about 0.125 to 10, e.g. about 0.3 to 3.

10 Another type of substituted cyclodextrins is sulfobutylcyclodextrines.

The ratio of the compound of formula (I) over the water soluble polymer may vary widely. For example ratios of 1/100 to 100/1 may be applied. Interesting ratios of the compound of formula (I) over cyclodextrin range from about 1/10 to 10/1. More 15 interesting ratios range from about 1/5 to 5/1.

Those of skill in the prevention of HIV-infection could determine the effective daily amount from the test results presented here. The exact dosage depends on the particular compound of formula (I) used.

20 In order to provide for an increased protection against HIV infection the compounds of formula (I) can also be combined with another or other antiretrovirals. Thus, the present invention also provides for a pharmaceutical composition according to the invention comprising a compound of formula (I) and further comprising one or more additional antiretroviral compounds. The present invention also relates to a product containing (a) a compound of formula (I), and (b) one or more additional antiretroviral compounds, as a combined preparation for simultaneous, separate or sequential use in HIV infection prevention. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers. Said other antiretroviral compounds 25 may be known antiretroviral compounds such as suramine, pentamidine, thymopentin, castanospermine, dextran (dextran sulfate), foscarnet-sodium (trisodium phosphono formate); nucleoside reverse transcriptase inhibitors, e.g. zidovudine (3'-azido-3'-deoxythymidine, AZT), didanosine (2',3'-dideoxyinosine; ddI), zalcitabine (dideoxycytidine, ddC) or lamivudine (2'-3'-dideoxy-3'-thiacytidine, 3TC), stavudine 30 (2',3'-didehydro-3'-deoxythymidine, d4T), abacavir and the like; non-nucleoside reverse transcriptase inhibitors such as nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one), efavirenz, delavirdine, 35

-28-

TMC-120, TMC-125 and the like; phosphonate reverse transcriptase inhibitors, e.g. tenofovir and the like; compounds of the TIBO (tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and thione)-type e.g. (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione;

5 compounds of the α -APA (α -anilino phenyl acetamide) type e.g. α -[(2-nitrophenyl)amino]-2,6-dichlorobenzene-acetamide and the like; inhibitors of trans-activating proteins, such as TAT-inhibitors, e.g. RO-5-3335, or REV inhibitors, and the like; protease inhibitors e.g. indinavir, ritonavir, saquinavir, lopinavir (ABT-378), nelfinavir, amprenavir, TMC-126, BMS-232632, VX-175 and the like; fusion

10 inhibitors, e.g. T-20, T-1249 and the like; CXCR4 receptor antagonists, e.g. AMD-3100 and the like; inhibitors of the viral integrase; nucleotide-like reverse transcriptase inhibitors, e.g. tenofovir and the like; ribonucleotide reductase inhibitors, e.g. hydroxyurea and the like.

15 By administering the compounds of the present invention with other anti-viral agents which target different events in the viral life cycle, the prophylactic effect of these compounds can be potentiated. Combination therapies as described above may exert a synergistic effect in inhibiting HIV replication because each component of the combination acts on a different site of HIV replication. The use of such combinations

20 may reduce the dosage of a given conventional anti-retroviral agent which would be required for a desired prophylactic effect as compared to when that agent is administered as a monotherapy. These combinations reduce potential of resistance to single agent therapies, while minimizing any associated toxicity. These combinations may also increase the efficacy of the conventional agent without increasing the

25 associated toxicity.

In addition to the above-described combination of the present compounds with another or other antiretrovirals, the compounds of the present invention may also be administered in combination with art-known microbicides. They can block the

30 infection by creating a barrier between the pathogen, in this case the Human Immunodeficiency Virus, and the site at which transmission will take place, e.g. the vagina; they can kill or immobilize the pathogen; they can prevent a virus from replicating once it has infected the cells that line the site of transmission, e.g. the cells that line the vaginal wall. Examples of microbicides are

35 a) antibodies. Scientists have found ways to isolate antibodies that counteract HIV and to mass-produce them. Therefore, these HIV antibodies can be combined with the present compounds of formula (I) to prevent HIV infection.

-29-

b) Detergents and surfactants. These compounds are able to disrupt the outer shell of viruses and therefore are useful as microbicide and they can be combined with the present compounds of formula (I) to prevent HIV infection. Examples of such detergents and surfactants are nonoxynol-9 and octoxynol-9, but all detergents and surfactants that are commonly used in shampoos, toothpastes and cleaning solutions, contact lens solutions are equally suitable.

5 c) Coatings for the site of transmission, i.e. coatings for the site of administration of the pharmaceutical composition, such as for example gels. These products may prevent HIV from entering the cells lining the site of transmission, e.g. the vaginal lining. Examples are sulphated and sulphonated polymers such as PC-515 (carrageenan), Pro-2000, dextrin 2 sulphate.

10 d) Peptides. Peptides are small protein molecules that line every surface of the body, e.g. skin, tongue, intestinal tract, and they may kill pathogens within minutes of contact. Thus, if applied at the site of potential transmission of HIV, peptides may kill off the pathogens before they cause infection.

15 e) pH regulators, especially for the vagina. These compounds regulate the natural acidity of the vagina making it inhospitable for the HIV. The natural vaginal environment is too acidic for HIV to survive, but semen is alkaline and the vagina becomes more alkaline during intercourse, allowing HIV to survive. By administering pH regulating compounds the alkaline environment that is created by semen can be countered. PH regulators encompass the use of Lactobacillus bacteria that produce hydrogen peroxide and thereby help to keep the vaginal environment healthy and acidic.

20

25 In the compositions of the present invention, one or more or all of the above-listed categories of microbicides may be combined with a compound of formula (I). Thus, the present invention also relates to a pharmaceutical composition according to the invention comprising a compound of formula (I) and further comprising one or more components wherein the components are selected from antibodies, detergents or

30 surfactants, coatings for the site of administration of the pharmaceutical composition, peptides, pH regulators. The present invention also relates to a product containing (a) a compound of formula (I), and (b) one or more components selected from antibodies, detergents or surfactants, coatings for the site of administration of the pharmaceutical composition, peptides, pH regulators, as a combined preparation for simultaneous, separate or sequential use in HIV infection prevention. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

35

-30-

The present invention relates also to a pharmaceutical composition as outlined hereinabove further comprising a spermicidal compound. Said compositions are able to prevent at the same time conception and HIV infection. Suitable spermicides are for example nonoxynol-9, octoxynol-9, menfegol, benzalkonium chloride, N-docasanol.

5


Although the present invention focuses on the use of the present compounds for preventing HIV infection via sexual intercourse or related intimate contact between partners, the present compounds may also be used as inhibitory agents for the prevention of infections caused by other viruses which depend on similar reverse transcriptases for obligatory events in their life cycle.

10

The following Tables 1, 2 and 3 list compounds of formula (I).

Table 1

15


















| Comp No. | R ³ | R ⁴ | Physical data mp. °C / (MH+)* |
|----------|--------------------|----------------|-------------------------------------|
| 2 | 2-benzofuranyl | H | mp. > 240 |
| 21 | 3-thienyl | H | mp. 220 |
| 3 | 2-furanyl | H | mp. 228 |
| 28 | 2-thienyl | H | mp. 235 |
| 29 | phenyl | H | mp. 230 |
| 1 | -CH=CH-CN | H | mp. 245, (E) |
| 30 | 2,4-dichlorophenyl | H | (460) |
| 31 | 2-benzo[b]thienyl | H | (448) |
| 32 | 1-naphthalenyl | H | (442) |
| 33 | 3-chlorophenyl | H | (426) |
| 34 | 3-acetylphenyl | H | (434) |
| 35 | 3-methylphenyl | H | (406) |
| 36 | 2-naphthalenyl | H | (442) |
| 37 | 4-chlorophenyl | H | (426) |

-31-

| Comp No. | R ³ | R ⁴ | Physical data mp.°C / (MH+)* |
|----------|---|----------------|------------------------------------|
| 38 | 4-methoxyphenyl | H | (422) |
| 39 | 4-methylthiophenyl | H | (438) |
| 40 | | H | |
| 19 | | H | mp.220 |
| 8 | -C(=N-OH)-CH(CH ₃) ₂ | H | mp. 156 |
| 20 | | H | mp. 205 |
| 27 | | H | mp. 193 |
| 41 | | H | mp. 200 |
| 42 | | H | mp.155 |
| 43 | | H | mp. 110 |
| 44 | | H | mp. 110 |
| 45 | -C(=N-OH)-CH ₃ | H | mp.135 |
| 9 | -C(=N-O-CH ₃)-CH(CH ₃) ₂ | H | mp. 185 |
| 46 | | H | mp. 164 |
| 47 | -CH ₂ -N(CH ₂ -CH ₃) ₂ | H | mp. 150 |
| 48 | | H | mp. 85 |
| 15 | | H | (461) |
| 49 | | H | (449) |
| 50 | | H | (487) |
| 51 | | H | (493) |










-32-

| Comp No. | R ³ | R ⁴ | Physical data mp. °C / (MH+)* |
|----------|--|----------------|-------------------------------------|
| 52 |  | H | (473) |
| 53 |  | H | (443) |
| 54 |  | H | (446) |
| 55 |  | H | (449) |
| 56 |  | H | (521) |
| 57 |  | H | (457) |
| 6 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -N(CH ₃) ₂ | H | (430) |
| 58 |  | H | (506) |
| 59 |  | H | (428) |
| 60 |  | H | (532) |
| 61 |  | H | (504) |
| 62 |  | H | (503) |
| 63 |  | H | (472) |
| 64 |  | H | (491) |
| 65 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₂ -CH ₃ | H | (415) |
| 66 |  | H | (442) |
| 67 |  | H | (410) |
| 68 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₃ | H | (401) |
| 69 |  | H | (399) |

-33-

| Comp No. | R ³ | R ⁴ | Physical data mp.°C / (MH+)* |
|----------|--|----------------|------------------------------------|
| 70 | | H | (396) |
| 71 | -CH ₂ -N(CH ₂ -CH ₂ -O-CH ₃) ₂ | H | (461) |
| 72 | | H | (485) |
| 73 | | H | (456) |
| 74 | | H | (492) |
| 75 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN | H | (412) |
| 76 | | H | (443) |
| 77 | | H | (397) |
| 78 | | H | (417) |
| 79 | | H | (464) |
| 80 | -CH ₂ -NH-CH ₂ -CH ₂ -N(CH ₂ -CH ₃) ₂ | H | mp, 105 |
| 81 | | H | mp. 240 |
| 82 | | H | mp. 170 |
| 24 | -CH ₂ -CH ₂ -CN | H | mp. 208 |
| 83 | | H | mp.>250°C |
| 14 | | H | mp.158 |
| 84 | -C(CH ₃)=CH-CN | H | mp.224°C (E) |
| 18 | -CH(OH)-CH ₂ -CN | H | mp.252°C |
| 85 | | H | (474) |
| 86 | | H | (473) |

-34-

| Comp No. | R ³ | R ⁴ | Physical data mp.°C / (MH+)* |
|----------|---|------------------|------------------------------------|
| 87 |  | H | (426) |
| 88 |  | H | (424) |
| 89 |  | H | (446) |
| 90 |  | H | (397) |
| 91 |  | H | (438) |
| 92 |  | H | (438) |
| 93 |  | H | (410) |
| 94 |  | H | (410) |
| 95 |  | H | (478) |
| 96 |  | H | (473) |
| 103 | -CH=C(CH ₃)-CN | H | mp. 201°C (E) |
| 11 | -CH=C(CH ₃)-CN | H | mp. 246°C (Z) |
| 10 | -CH=CH-CN | H | mp. 258°C (Z) |
| 4 | -CH ₂ -CN | H | |
| 17 |  | H | mp. 110°C |
| 97 |  | H | mp. 240°C |
| 16 |  | H | mp.>250°C |
| 7 | -CH ₂ -O-CH ₂ -CH ₂ -CN | H | mp>260 |
| 5 | 4-thiomorpholinyl | -NO ₂ | mp. 268 |
| 98 | 4-morpholinyl | -NO ₂ | mp. 210 |


| Comp No. | R ³ | R ⁴ | Physical data mp. °C / (MH+)* |
|----------|--|--------------------------------------|-------------------------------------|
| 22 | 1-piperidinyl | -NO ₂ | mp. 252 |
| 23 | 1-piperidinyl | -NH ₂ | mp. 262 |
| 12 | H | -C(CH ₃)=CH-CN (E) (381) | |
| 13 | H | -C(CH ₃)=CH-CN (Z) (381) | |
| 127 | -N(CH ₃) ₂ | H | mp. 228°C |
| 123 | -C(=O)-CH ₂ -CN | H | mp. 150°C |
| 116 | | H | (463) |
| 128 | | H | (480) |
| 129 | | H | (452) |
| 130 | -CH=N-NH-C(=O)-CH ₃ | H | (400) |
| 131 | -CH=N-NH-C(=O)-CH ₂ -CN | H | (425) |
| 132 | | H | (468) |
| 115 | -C(=O)-NH-CH ₃ | H | (373) |
| 134 | -C(=O)-N(CH ₃) ₂ | H | (387) |
| 135 | -C(=O)-N(CH ₃)-CH ₂ -CH ₃ | H | (401) |
| 136 | -C(=O)-N(CH ₂ -CH ₃) ₂ | H | (415) |
| 137 | -C(=O)-NH-CH ₂ -CH ₃ | H | (387) |
| 138 | -C(=O)-NH-CH ₂ -CN | H | (398) |
| 139 | -C(=O)-N(CH ₃)-CH ₂ -CN | H | (412) |
| 140 | -C(=O)-NH-CH ₂ -C≡CH | H | (397) |
| 141 | -C(=O)-NH-CH ₂ -CH=CH ₂ | H | (399) |
| 142 | -C(=O)-NH-CH(CH ₃) ₂ | H | (401) |
| 143 | -N[CH ₂ -CH(CH ₃) ₂] ₂ | H | mp. 238°C |
| 144 | -CH ₂ -CH(CN) ₂ | H | mp. 160°C |
| 106 | -CH=C(CN)-C(=O)-C(CH ₃) ₃ | H | (E), mp. 193°C |
| 145 | | H | (E), mp. 229°C |

| Comp No. | R ³ | R ⁴ | Physical data mp. °C / (MH+)* |
|----------|--|----------------|-------------------------------------|
| 146 | | H | (Z), mp. 258°C |
| 147 | -CH=C(CN)-CH ₂ -CN | H | (Z/E=88/12) (406) |
| 148 | -C(CH ₂ -CH ₃)=CH-CN | H | (E), mp. 173°C |
| 149 | -C(CH(CH ₃) ₂)=CH-CN | H | (E), mp. 132°C |
| 150 | -C(CH(CH ₃) ₂)=CH-CN | H | (Z), mp. 132°C |
| 151 | -CH=C(CH ₃)-CN | H | (Z), mp. 246°C |
| 152 | -CH=C(CH ₃)-CN | H | (E), mp. 201°C |
| 153 | -CH ₂ -CH(CH ₃)-CN | H | mp. 187°C |
| 124 | -C(Cl)=CH-CN | H | |
| 154 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CN | H | (E) |
| 112 | -CH=CH-C(=O)-N(CH ₃) ₂ | H | (E), mp.>264°C |
| 155 | | H | (E), mp. 156°C |
| 156 | | H | (E), mp. 168°C |
| 157 | | H | (E), mp.>265°C |
| 158 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₃ | H | (E), mp.>260°C |
| 114 | -CH=CH-C(=O)-N(CH ₃)-(CH ₂) ₂ -CN | H | (E), mp. 168°C |
| 159 | -CH=CH-C(=O)-N(CH ₂ -CH ₃) ₂ | H | (E), mp. 249°C |
| 160 | -C(CH ₃)=C(CH ₃)-CN | H | (E) |
| 107 | -CH=CH-Cl | H | (Z), mp. 250°C |
| 161 | -CH=CH-Br | H | (Z), mp. 248°C |
| 111 | -CH=C(Br) ₂ | H | mp. 223°C |
| 122 | | H | (E), mp. 120°C |
| 162 | | H | (E), mp. >260°C |
| 163 | | H | mp. 128°C |

-37-








| Comp No. | R ³ | R ⁴ | Physical data mp. °C / (MH+)* |
|----------|--|-----------------------------------|----------------------------------|
| 164 | | H | mp. 104°C |
| 125 | | H | |
| 104 | | H | |
| 165 | | H | mp. 112°C |
| 166 | | H | mp. 194°C |
| 167 | | H | mp. 191°C |
| 126 | | H | mp. >260°C |
| 168 | -CH ₂ -O-CH ₂ -CH ₃ | H | mp. 201°C |
| 117 | H | -N(CH ₃) ₂ | mp. 132°C |
| 120 | -CH=C(CN) ₂ | H | |
| 253 | -CH=CH-C(=O)NH ₂ | H | (E) |
| 254 | -CH=CH-C(=O)NH ₂ | H | (E) HCl |

* (MH⁺) defines the mass of the protonated compound; it was determined with a MicroMass spectrometer equipped with an electrospray probe with a quadripolar analyser.

5 Table 2:

| Comp No. | R ³ | R ¹ | Physical data mp. °C / (MH+)* |
|----------|---|----------------|----------------------------------|
| 25 | -CH=CH-CN | H | mp. 256°C |
| 99 | -CH ₂ CN | H | mp. 184°C |
| 100 | -CH ₂ N(CH ₂ CH ₃) ₂ | H | mp. 172 °C |




-38-

| Comp No. | R ³ | R ¹ | Physical data mp. °C / (MH+)* |
|----------|--|-----------------|----------------------------------|
| 102 | -CH ₂ -CH ₂ -CN | H | mp. 224°C |
| 101 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN | H | mp. 196°C |
| 26 | -CH=CH-CN | CH ₃ | mp. 195°C |
| 169 | -C(=O)-N(CH ₂ -CH ₃) ₂ | H | mp. 172°C |
| 170 | -CH ₂ -N(CH ₃)-CH ₂ -CN | H | |
| 171 |  | H | (398) |
| 172 |  | H | mp. 158°C |
| 173 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -N(CH ₃) ₂ | H | mp. 196°C |
| 174 | -CH ₂ -N(CH ₃)-CH=N-CN | H | mp. 254°C |
| 175 | 2-furanyl | CH ₃ | mp. 178°C |
| 118 |  | H | 164°C |
| 176 |  | CH ₃ | mp. 188°C |
| 177 | -CH=CH-Br | H | (Z), mp. 169°C |
| 110 | -CH=C(F)-CN | H | (E), mp. 254°C |
| 178 | -CH=C(CH ₃)-CN | H | (Z) |
| 179 | -CH=C(CH ₃)-CN | H | (E) |
| 180 |  | H | (E) |
| 181 | -CH=CH-C(=O)-NH-cyclopropyl | H | (E) (426) |
| 182 | -CH=CH-C(=O)-NH-CH ₂ -CH ₂ -N(CH ₃) ₂ | H | (E) (427) |
| 183 | -CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -O-CH ₃ | H | (E)(458) |
| 184 | -CH=CH-C(=O)-NH-CH ₂ -CH(CH ₃) ₂ | H | (E)(442) |
| 185 | -CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CN | H | (E)439) |
| 186 |  | H | (E)(468) |
| 187 | -CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -N(CH ₃) ₂ | H | (E)(471) |
| 188 | -CH=CH-C(=O)-NH-(CH ₂) ₃ -O-CH ₂ -CH ₃ | H | (E)(472) |
| 189 | -CH=CH-C(=O)-NH-CH ₂ -CH ₃ | H | (E)(414) |
| 190 | -CH=CH-C(=O)-NH-CH ₂ -CH ₂ -O-CH ₃ | H | (E)(444) |
| 191 | -CH=CH-C(=O)-NH-CH(CH ₃) ₂ | H | (E)(428) |
| 192 |  | H | (E)(491) |


-39-

| Comp No. | R ³ | R ¹ | Physical data mp. °C / (MH+)* |
|----------|---|----------------|----------------------------------|
| 193 | | H | (E)(444) |
| 194 | -CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN | H | (E)(439) |
| 195 | | H | (E)(483) |
| 196 | -CH=CH-CH ₂ -N(CH ₂ -CH ₂ -O-CH ₃) ₂ | H | (E)(488) |
| 197 | | H | (E)(476) |
| 198 | -CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₃ | H | (E)(428) |
| 199 | -CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -N(CH ₂ -CH ₃) ₂ | H | (E)(485) |
| 200 | -CH=CH-CH ₂ -N(CH ₂ -CH ₃)-CH ₃ | H | (E)(414) |
| 201 | -CH=CH-CH ₂ -N(CH ₂ -CH ₂ -CH ₃) ₂ | H | (E)(456) |
| 202 | -CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₂ -CH ₃ | H | (E)(442) |
| 203 | | H | (E)(438) |
| 204 | | H | (E)(442) |
| 205 | | H | (E)(455) |
| 206 | -CH=CH-CH ₂ -N(benzyl)-CH ₂ -CH ₂ -N(CH ₃) ₂ | H | (E)(533) |
| 207 | -CH=CH-CH ₂ -N(CH ₃) ₂ | H | (E)(457) |
| 208 | -CH=CH-CH ₂ -N(isopropyl) ₂ | H | (E)(456) |
| 121 | -CH=CH-C(=O)-NH ₂ | H | (E) |
| 209 | | H | (E), mp. 116°C |
| 210 | | H | (E), mp. 254°C |
| 211 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -OH | H | (E), mp. 222°C |
| 212 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CN | H | (E), mp. 198°C |
| 213 | -C(CH ₃)=CH-CN | H | (E) |
| 214 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -CN | H | (E), mp. 204°C |
| 215 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₃ | H | (E), mp. 211°C |
| 216 | | H | (E), mp. 246°C |
| 217 | -CH=CH-C(=O)-N(CH ₂ -CH ₃) ₂ | H | (E), mp. 226°C |

-40-

| Comp No. | R ³ | R ¹ | Physical data mp.°C / (MH+)* |
|----------|---|----------------|------------------------------|
| 218 |  | H | (E), mp. 196°C |
| 219 | -CH=CH-C(=O)-N(CH ₃) ₂ | H | (E), mp. 225°C |
| 220 | -CH=C(CN)-CH ₂ -CN | H | (Z), mp. 195°C |
| 109 | -CH=CH-Cl | H | (E), mp. 200°C |
| 108 | -CH=CH-Cl | H | (Z), mp. 165°C |
| 221 | -CH=CH-C(=O)-NH-CH ₃ | H | (E), mp. 260°C |
| 222 | -CH=CH-C(=O)-N(CH ₂ -CH ₂ -O-CH ₃) ₂ | H | (E), mp. 158°C |
| 223 |  | H | (E), mp. 208°C |
| 224 |  | H | (E), mp. 208°C |
| 113 | -CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -CH ₂ -CH ₃ | H | (E), mp. 212°C |
| 225 | -CH ₂ -N(CH ₂ -CH ₂ -CN) ₂ | H | mp. 154°C |
| 226 | 2-furanyl | H | mp. 162°C |
| 255 | -CH=CH-CN | H | (E) |

* (MH⁺) defines the mass of the protonated compound; it was determined with a MicroMass spectrometer equipped with an electrospray probe with a quadripolar analyser.

5 Table 3:

| Comp No. | R ³ | R ^{4a} | R ^{4b} | X ¹ | Physical data mp.°C |
|----------|---|-----------------|-----------------|----------------|---------------------|
| 227 | -CH ₂ -CH ₂ -CN | CH ₃ | H | -NH | mp. 186°C |
| 228 | -CH ₂ -N(CH ₃)-CH ₂ -CN | CH ₃ | H | -NH | mp. 138°C |
| 229 | -CH=C(CH ₃)-CN | CH ₃ | H | -NH | mp. 190°C |
| 230 | -CH=CH-CN | CH ₃ | H | -O- | (E), mp. 254°C |
| 231 | -CH=C(CH ₃)-CN | CH ₃ | H | -O- | mp. 150°C |
| 232 | -C(CH ₃)=CH-CN | CH ₃ | H | -O- | (E), mp. 234°C |
| 105 | -CH ₂ -O-CH ₂ -CH ₃ | CH ₃ | H | -O- | mp. 140°C |

-41-

| Com p No. | R ³ | R ^{4a} | R ^{4b} | X ¹ | Physical data mp.°C |
|-----------------|---|-----------------|-------------------|----------------|------------------------|
| 233 | -CH=C(CH ₃)-CN | CH ₃ | Cl | -NH | mp. 214°C |
| 234 | -CH ₂ -CH ₂ -CN | CH ₃ | H | -O- | mp. 199°C |
| 235 | -CH(CH ₃)-CH ₂ -CN | CH ₃ | H | -O- | mp. 195°C |
| 236 | -CH ₂ -CH(CH ₃)-CN | CH ₃ | H | -O- | mp. 161°C |
| 237 | -CH=CH-CN | CH ₃ | H | -NH | (E), mp. >264°C |
| 238 | -CH ₂ -CN | CH ₃ | Cl | -NH | mp. 184°C |
| 239 | -CH=CH-CN | CH ₃ | 2-furanyl | -NH | (E) mp. 175°C |
| 119 | -CH=C(CN)-CH ₂ -CN | CH ₃ | 2-furanyl | -NH | |
| 240 |  | CH ₃ | Cl | -NH | mp. 248°C Z/E=50/50 |
| 241 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN | CH ₃ | Br | -NH | mp. 148°C |
| 242 | -CH=CH-CN | H | isopropyl | -NH | (E) 30%-(Z) 70% |
| 243 | -CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN | CH ₃ | Cl | -NH | mp. 85°C |
| 244 | -CH=CH-CN | H | Br | -NH | (E), mp. 270°C |
| 245 | -CH=CH-CN | H | -OCH ₃ | -NH | (E), mp. 258°C |
| 246 | -C(CH ₃)=C(CH ₃)-CN | CH ₃ | H | -O- | (E), mp. 214°C |
| 247 | -CH=C(CH ₃)-CN | CH ₃ | Br | -NH | mp. 212°C |
| 248 | -CH=CH-CN | CH ₃ | Br | -NH | (E), mp. 250°C |
| 249 | -CH=C(CH ₃)-CN | H | -OCH ₃ | -NH | mp. 166°C |
| 250 | -CH=C(CH ₃)-CN | H | Br | -NH | mp. 186°C |
| 251 | -CH ₂ -CH ₂ -CN | H | -OCH ₃ | -NH | mp. 228°C |
| 252 | -CH ₂ -O-CH ₂ -CH ₂ -CN | H | Cl | -NH | mp. 168°C |
| 133 | -CH=CH-CN | CH ₃ | Cl | -NH | (E), mp. 258°C |

Pharmacological example

A) In vitro models to test the ability of compounds to prevent HIV infection via sexual intercourse or related intimate contact between partners.

In order to demonstrate the ability of the present compounds to prevent HIV infection via sexual intercourse or related intimate contact between partners, the compounds of formula (I) are tested in the following test. Immature monocyte derived dendritic cells (immMO-DC) represent a good model for interstitial dendritic cells, which are early

-42-

targets during sexual HIV transmission and important initiators of the immune response. These immMO-DC were used in "in vitro" models to test the prevention of HIV infection via sexual intercourse or related intimate contact between partners.

5 *In vitro model a)*

The monotropic HIV strain Ba-L is pre-incubated with the compound of formula (I) (test compound). To the mixture of virus and test compound, immMO-DC are added and incubated for 2 hours at 37 °C. After infection, cells are washed 6 times and cultured with autologous CD4(+) T cells (ratio immMO-DC/ CD4(+) T : 1/10). Test 10 compound is re-added and remains present during 14 days of primary culture, after which cells are extensively washed and PHA/IL-2 stimulated blasts are added (secondary culture, no test compound present). Supernatants are analysed in ELISA during primary and secondary culture. To determine antiviral activity, the test compound concentration able to suppress 50% of the viral replication at the end of the 15 primary cultures (EC50) is measured. Additionally, cells are harvested after 3 weeks of secondary culture and analysed for the presence of HIV proviral DNA (PCR), to check for sterilisation and exclude viral rescue.

In vitro model b) (24 hour infection experiment)

20 Monocyte-derived dendritic cells (MO-DC) were co-cultured with autologous T4 cells and infected with HIV strain Ba-L at a multiplicity of infection (MOI) of 10^{-3} . A serial dilution of test compound was added at the time of infection. After 24 hours, 96-well plates were washed 3 times (test compound and free virus washed away) and medium (without test compound) was added. Half of the medium was refreshed twice a week. 25 Culture supernatants were harvested after 7 and 14 days of culture. After 14 days, cultures were washed 3 times and PHA/IL-2 stimulated PBMC were added for a secondary culture to check for viral rescue. During secondary culture, half of the medium was refreshed twice weekly (IL-2 medium, without test compound). Supernatants were harvested after 1 and 2 weeks of secondary culture. After 2 weeks 30 of secondary culture, cells were also harvested for PCR analysis. Supernatants were analysed in ELISA for the presence of HIV proviral DNA during primary and secondary culture.

After 7 days of primary culture, none out of 6 cups tested positive in ELISA for 35 compound 230 for concentrations ranging from 10,000 to 100 nM. After 7 days of primary culture, none out of 6 cups tested positive in ELISA for compound 255 for concentrations ranging from 10,000 to 10 nM.

In vitro model c) (standard infection experiment)

Monocyte-derived dendritic cells (MO-DC) were infected for 2 hours with the
monotropic HIV strain Ba-L at a multiplicity of infection (MOI) of 10^3 . After infection,
5 cells were washed 6 times and resuspended in 10% BCS at 400.000 cells/ml.
Autologous CD4(+) T cells were purified out of the lymphocyte fraction of the same
elutriation as the MO-DC and used at a concentration of 2×10^6 cells/ml ((ratio
MO-DC/CD4(+) T : 1/5).
A serial dilution of a compound of formula (I) (test compound) was added to the MO-DC/
10 CD4(+) T cell co-cultures. Each experiment was done in 96-well plates, in which each
cup contained 50µl of MO-DC, 50µl of CD4(+) T cells and 100µl of test compound. Half
of the culture medium, with test compound, was refreshed twice weekly, during 14 days.
Supernatants were analysed by ELISA after 14 days of culture for the presence of HIV
antigens. To determine antiviral activity, the test compound concentration able to
15 suppress 50% of the viral replication at the end of the primary cultures (EC50) was
measured.

B) Immune suppressive activity of the present compounds tested in Mixed Leucocyte
Culture (MLC)

20 The compounds of formula (I) were tested for their immune-suppressive activity (defined
as ISC₅₀ value) in a classical MLC in which monocyte-derived dendritic cells (MO-DC)
were used as stimulators and allogenic CD4(+) T cells as responders.

A dilution series of test compound was added to the MO-DC/ CD4(+) T cell co-cultures.
25 After 5 days of culture, 20µl of [methyl-³H]-Thymidine was added to each well and
cultures were harvested after 7 hours. Analysis was done on a Topcount scintillation
counter. The immune suppressive concentration (ISC₅₀) is defined as the test compound
concentration inhibiting 50% of normal immune proliferation (test compound
concentration inhibiting 50% of [methyl-³H]-Thymidine incorporation). (standard MLC
30 assay)

For the 24 hour assay, the test compound was only present during the first 24 hours of the
5-day culture period. After 24 hours, the cultures were washed (three times) and culture
medium without compound was added. The experimental set-up was from then on
similar to the standard MLC assay described above.

35 Tables 4 and 5 list the results obtained in the above-indicated tests. From these results it
can be concluded that the tested compounds efficiently block HIV infection in MO-DC/

-44-

CD4(+) T cell co-cultures. Immune suppression was only found at much higher concentrations. Therefore, the compounds of the present invention can be considered as novel microbicides.

5 Table 4 :


| Comp. No. | EC ₅₀ (nM) (<i>in vitro</i> model c)) | ISC ₅₀ (nM) (Test B, standard assay)) |
|-----------|---|--|
| 248 | 0.55 | 1,5553 |
| 24 | 0.55 | 675 |
| 151 | 2 | 385 |
| 231 | 3 | 18,690 |
| 1 | 0.42 | 1,216 |
| 230 | 0.24 | 43,208 |
| 162 | 5.5 | 1,141 |
| 250 | 3 | 4,500 |
| 242 | 3 | |
| 255 | 0.05 | 20,240 |

Table 5 :

| Comp. No. | EC ₅₀ (nM) (<i>in vitro</i> model b)) | ISC ₅₀ (nM) (Test B, 24 hour assay)) |
|-----------|---|---|
| 1 | 1 | 22,221 |
| 230 | 8 | > 100,000 |
| 255 | 2 | 24,635 |

Claims

1. Use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse or related intimate contact between partners, wherein the compound has the formula



5

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

$-a^1-a^2-a^3-a^4-$ represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);

10 -N=CH-CH=CH- (a-2);

-N=CH-N=CH- (a-3);

-N=CH-CH=N- (a-4);

-N=N-CH=CH- (a-5);

$-b^1=b^2-b^3=b^4-$ represents a bivalent radical of formula

15 -CH=CH-CH=CH- (b-1);

-N=CH-CH=CH- (b-2);

-N=CH-N=CH- (b-3);

-N=CH-CH=N- (b-4);

-N=N-CH=CH- (b-5);

20 n is 0, 1, 2, 3 or 4; and in case $-a^1=a^2-a^3=a^4-$ is (a-1), then n may also be 5;

m is 1, 2, 3 and in case $-b^1=b^2-b^3=b^4-$ is (b-1), then m may also be 4;

R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl;

C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl,

C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with

25 C₁₋₆alkyloxycarbonyl;

each R² independently is hydroxy, halo, C₁₋₆alkyl optionally substituted with cyano or

-C(=O)R⁶, C₃₋₇cycloalkyl, C₂₋₆alkenyl optionally substituted with one or more

halogen atoms or cyano, C₂₋₆alkynyl optionally substituted with one or more halogen


atoms or cyano, C₁₋₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or

30 di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶,

-C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of

formula

-46-



wherein each A_1 independently is N, CH or CR^6 ; and

A_2 is NH, O, S or NR^6 ;

X_1 is $-NR^5$, $-NH-NH$, $-N=N$, $-O$, $-C(=O)$, C_{1-4} alkanediyl, $-CHOH$, $-S$, $-S(=O)_p$,

5 $-X_2-C_{1-4}$ alkanediyl- or $-C_{1-4}$ alkanediyl- X_2 ;

X_2 is $-NR^5$, $-NH-NH$, $-N=N$, $-O$, $-C(=O)$, $-CHOH$, $-S$, $-S(=O)_p$;

R^3 is NHR^{13} ; $NR^{13}R^{14}$; $-C(=O)-NHR^{13}$; $-C(=O)-NR^{13}R^{14}$; $-C(=O)-R^{15}$; $-CH=N-NH-C(=O)-R^{16}$; C_{1-6} alkyl substituted with one or more substituents each

10 independently selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{1-6} alkyl substituted with one or more substituents each independently

selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by C_{1-4} alkanediyl; C_{1-6} alkyl substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ;

15 C_{1-6} alkyloxy C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{2-6} alkenyl substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{2-6} alkynyl substituted with one or more substituents each independently

20 selected from halo, cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; $-C(=N-O-R^8)-C_{1-4}$ alkyl; R^7 or $-X_3-R^7$;

X_3 is $-NR^5$, $-NH-NH$, $-N=N$, $-O$, $-C(=O)$, $-S$, $-S(=O)_p$, $-X_2-C_{1-4}$ alkanediyl-, $-C_{1-4}$ alkanediyl- X_{2a} , $-C_{1-4}$ alkanediyl- $X_{2b}-C_{1-4}$ alkanediyl, $-C(=N-OR^8)-C_{1-4}$ alkanediyl-;

25 with X_{2a} being $-NH-NH$, $-N=N$, $-O$, $-C(=O)$, $-S$, $-S(=O)_p$; and with X_{2b} being $-NH-NH$, $-N=N$, $-C(=O)$, $-S$, $-S(=O)_p$;

R^4 is halo, hydroxy, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy, aminocarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, formyl, amino, mono- or di(C_{1-4} alkyl)amino or R^7 ;

30 R^5 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl or C_{1-6} alkylcarbonyloxy; C_{1-6} alkyloxy C_{1-6} alkylcarbonyl substituted with C_{1-6} alkyloxycarbonyl;

R^6 is C_{1-4} alkyl, amino, mono- or di(C_{1-4} alkyl)amino or polyhalo C_{1-4} alkyl;

-47-

R^7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁-6alkyl, hydroxyC₁-6alkyl, aminoC₁-6alkyl, mono or di(C₁-6alkyl)aminoC₁-6alkyl, formyl, C₁-6alkylcarbonyl, C₃-7cycloalkyl, C₁-6alkyloxy, C₁-6alkyloxycarbonyl, C₁-6alkylthio, cyano, nitro, polyhaloC₁-6alkyl, polyhaloC₁-6alkyloxy, aminocarbonyl, -CH(=N-O-R⁸), R^{7a}, -X₃-R^{7a} or R^{7a}-C₁-4alkyl;

10 R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁-6alkyl, hydroxyC₁-6alkyl, aminoC₁-6alkyl, mono or di(C₁-6alkyl)aminoC₁-6alkyl, formyl, C₁-6alkylcarbonyl, C₃-7cycloalkyl, C₁-6alkyloxy, C₁-6alkyloxycarbonyl, C₁-6alkylthio, cyano, nitro, polyhaloC₁-6alkyl, polyhaloC₁-6alkyloxy, aminocarbonyl, -CH(=N-O-R⁸);

15 R^8 is hydrogen, C₁-4alkyl, aryl or arylC₁-4alkyl;

20 R^9 and R^{10} each independently are hydrogen; hydroxy; C₁-6alkyl; C₁-6alkyloxy; C₁-6alkylcarbonyl; C₁-6alkyloxycarbonyl; amino; mono- or di(C₁-6alkyl)amino; mono- or di(C₁-6alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁-6alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁-6alkyloxy, hydroxyC₁-6alkyloxy, carboxyl, C₁-6alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁-4alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

25 R^9 and R^{10} may be taken together to form a bivalent or trivalent radical of formula

| | |
|---|-------|
| -CH ₂ -CH ₂ -CH ₂ -CH ₂ - | (d-1) |
| -CH ₂ -CH ₂ -CH ₂ -CH ₂ -CH ₂ - | (d-2) |
| -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - | (d-3) |
| -CH ₂ -CH ₂ -S-CH ₂ -CH ₂ - | (d-4) |
| -CH ₂ -CH ₂ -NR ¹² -CH ₂ -CH ₂ - | (d-5) |
| -CH ₂ -CH=CH-CH ₂ - | (d-6) |
| =CH-CH=CH-CH=CH- | (d-7) |

30

35

-48-

R^{11} is cyano; C_{1-4} alkyl optionally substituted with C_{1-4} alkyloxy, cyano, amino, mono- or di(C_{1-4} alkyl)amino or aminocarbonyl; C_{1-4} alkylcarbonyl; C_{1-4} alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4} alkyl)aminocarbonyl;

R^{12} is hydrogen or C_{1-4} alkyl;

5 R^{13} and R^{14} each independently are C_{1-6} alkyl optionally substituted with cyano or aminocarbonyl, C_{2-6} alkenyl optionally substituted with cyano or aminocarbonyl, C_{2-6} alkynyl optionally substituted with cyano or aminocarbonyl;

R^{15} is C_{1-6} alkyl substituted with cyano or aminocarbonyl;


R^{16} is C_{1-6} alkyl optionally substituted with cyano or aminocarbonyl, or R^7 ;

10 p is 1 or 2;

 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono or di(C_{1-6} alkyl)amino C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylthio, cyano, nitro,

15 polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy, aminocarbonyl, R^7 or $-X_3-R^7$.

2. Use of a compound according to claim 1 wherein the compound has the formula



wherein

20 $-a^1=a^2-a^3=a^4$, $-b^1=b^2-b^3=b^4$, R^1 , R^2 , R^3 , R^4 , m and X_1 are as defined in claim 1;


n' is 0, 1, 2 or 3 and in case $-a^1=a^2-a^3=a^4$ is $(a-1)$, then n' may also be 4;

R^2' is halo, C_{1-6} alkyl, trihalomethyl, trihalomethoxy, cyano, aminocarbonyl, C_{1-6} alkyl substituted with cyano or aminocarbonyl;

 provided that R^2' is placed at the para position in respect of the NR^1 moiety.

25

3. Use of a compound according to claim 1 or 2 wherein the compound has the formula




wherein

$-b^1=b^2-b^3=b^4$, R^1 , R^2 , R^3 , R^4 , m and X_1 are as defined in claim 1;

30 n' and R^2' are as defined in claim 3.

-49-

4. Use of a compound according to any one of claims 1 to 3 wherein the compound has the formula



wherein

5 R¹, R², R³, R⁴ and X₁ are as defined in claim 1;
n' and R²' are as defined in claim 3.

5. Use of a compound according to any one of claims 2 to 4 wherein R²' is cyano, aminocarbonyl or C₁₋₆alkyl substituted with cyano or aminocarbonyl.

10

6. Use of a compound according to any one of claims 1 to 5 wherein the compound is selected from

4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile;

15 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[4-(2-cyanoethenyl)-2-methylphenoxy]-2-pyrimidinyl]amino]benzonitrile;
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a
stereochemically isomeric form thereof.

20 7. Use according to claim 6 wherein the compound is selected from

4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile (E);

4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]benzonitrile (E);

25 4-[[4-[4-(2-cyanoethenyl)-2-methylphenoxy]-2-pyrimidinyl]amino]benzonitrile (E).

8. Use according to any one of claims 1 to 7 wherein the sexual intercourse is vaginal, anal or oral sex.

30 9. Use according to claim 8 wherein the intercourse is vaginal sex.

10. Use according to any one of claims 1 to 9 wherein the medicament is in a form adapted to be applied to the site where the sexual intercourse or related intimate contact between partners takes place.

-50-

11. Use according to claim 10 wherein the medicament is in a form adapted to be applied to the vagina, rectum, mouth or skin.
- 5 12. Use according to claim 11 wherein the medicament is in the form of a gel, jelly, cream, ointment, film, sponge, foam, intravaginal ring, cervical cap, suppository for rectal or vaginal application, vaginal or rectal or buccal tablet, mouthwash.
- 10 13. Use according to any one of claims 1 to 12 wherein the HIV infection is a multidrug resistant HIV infection.
- 15 14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as defined in any one of claims 1 to 7 characterized in that the pharmaceutical composition is bioadhesive to the site of application.
- 20 15. A pharmaceutical composition as claimed in claim 14 wherein the site of application is the vagina, rectum, mouth or skin.
- 25 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as defined in any one of claims 1 to 7 characterized in that the pharmaceutical composition is in a form adapted to be applied to the vagina or mouth.
- 30 17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as defined in any one of claims 1 to 7 characterized in that the pharmaceutical composition is a gel, jelly, cream, film, sponge, foam, intravaginal ring, cervical cap, suppository for rectal or vaginal application, vaginal or rectal or buccal tablet, mouthwash.
- 35 18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as defined in any one of claims 1 to 7 characterized in that the pharmaceutical composition is in the form of a gel containing carbopol, hydroxypropyl cellulose, hydroxyethyl cellulose or pregelatinized starch.

-51-


19. A pharmaceutical composition as claimed in any one of claims 14 to 18 further comprising one or more additional antiretroviral compounds.

5 20. A pharmaceutical composition as claimed in any one of claims 14 to 19 further comprising one or more components selected from an antibody, a detergent or surfactant, a coating for the site of administration of the pharmaceutical composition, a peptide or a pH regulator.

10 21. A pharmaceutical composition as claimed in any one of claims 14 to 20 further comprising a spermicidal compound.

22. A compound of formula (I) as defined in claim 1 wherein the compound is

(E)



15 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereoisomeric form thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/001011

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D239/47 A61K31/505 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P, X | <p>WO 03/016306 A (KOYMANS LUCIEN MARIA HENRICUS ; LEWI PAULUS JOANNES (BE); VAN AKEN KOE) 27 February 2003 (2003-02-27) cited in the application</p> <p>page 1, line 7 - line 8</p> <p>page 1, formula (I)</p> <p>page 43, line 34 - line 35</p> <p>page 44, line 12</p> <p>page 48, line 26 - line 29</p> <p>page 51, line 25 - line 26</p> <p>page 98, Table 4, Compound No. 25</p> | 1-10, 14, 18-22 |

-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 May 2004

Date of mailing of the international search report

14/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5018 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/001011

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | WO 99/50250 A (AKEN KOEN JEANNE ALFONS VAN ; KOYMANS LUCIEN MARIA HENRICUS (BE); HEER) 7 October 1999 (1999-10-07) cited in the application page 1, line 6 - line 8 page 1, formula (I) page 20, line 13 page 22, line 10 - line 13 pages 35, 36, Table 6, Compounds No. 65-62 and 64-81 | 1-10, 14, 18-21 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/001011

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|--|------------------|
| WO 03016306 | A 27-02-2003 | CA 2452217 A1 | | 27-02-2003 |
| | | WO 03016306 A1 | | 27-02-2003 |
| | | EP 1419152 A1 | | 19-05-2004 |
| WO 9950250 | A 07-10-1999 | AT 232521 T | | 15-02-2003 |
| | | AU 751573 B2 | | 22-08-2002 |
| | | AU 3599699 A | | 18-10-1999 |
| | | BG 104738 A | | 30-04-2001 |
| | | BR 9909191 A | | 05-12-2000 |
| | | CA 2324919 A1 | | 07-10-1999 |
| | | CN 1295564 T | | 16-05-2001 |
| | | DE 69905306 D1 | | 20-03-2003 |
| | | DE 69905306 T2 | | 27-11-2003 |
| | | DK 945443 T3 | | 02-06-2003 |
| | | EA 2973 B1 | | 26-12-2002 |
| | | EE 200000532 A | | 15-02-2002 |
| | | WO 9950250 A1 | | 07-10-1999 |
| | | EP 1245567 A1 | | 02-10-2002 |
| | | EP 0945443 A1 | | 29-09-1999 |
| | | ES 2193660 T3 | | 01-11-2003 |
| | | HR 20000620 A1 | | 30-06-2001 |
| | | HU 0101204 A2 | | 28-10-2001 |
| | | ID 26291 A | | 14-12-2000 |
| | | JP 3507917 B2 | | 15-03-2004 |
| | | JP 2002509920 T | | 02-04-2002 |
| | | NO 20004810 A | | 26-09-2000 |
| | | NZ 506679 A | | 26-11-2002 |
| | | PL 343196 A1 | | 30-07-2001 |
| | | PT 945443 T | | 30-06-2003 |
| | | SI 945443 T1 | | 31-08-2003 |
| | | SK 14062000 A3 | | 11-06-2001 |
| | | TR 200002760 T2 | | 21-12-2000 |
| | | TW 531534 B | | 11-05-2003 |
| | | US 2003083317 A1 | | 01-05-2003 |
| | | US 6197779 B1 | | 06-03-2001 |
| | | US 2001011094 A1 | | 02-08-2001 |
| | | EP 0945442 A1 | | 29-09-1999 |
| | | ZA 200006044 A | | 26-10-2001 |